| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.066 | 0.09 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.096 | 0.1 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.1 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |